Compare GPOR & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPOR | RARE |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 1998 | 2013 |
| Metric | GPOR | RARE |
|---|---|---|
| Price | $174.90 | $26.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 20 |
| Target Price | ★ $233.33 | $59.10 |
| AVG Volume (30 Days) | 296.3K | ★ 2.1M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 245.92 | 7.31 |
| EPS | ★ 13.82 | N/A |
| Revenue | ★ $1,422,583,000.00 | $673,000,000.00 |
| Revenue This Year | $18.35 | $13.12 |
| Revenue Next Year | $6.04 | $37.80 |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | ★ 48.47 | 20.13 |
| 52 Week Low | $149.18 | $18.29 |
| 52 Week High | $225.78 | $39.89 |
| Indicator | GPOR | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 47.27 |
| Support Level | $173.75 | $24.22 |
| Resistance Level | $177.26 | $28.13 |
| Average True Range (ATR) | 4.03 | 1.14 |
| MACD | 0.58 | 0.14 |
| Stochastic Oscillator | 84.70 | 35.98 |
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets located in the Appalachia and Anadarko basins in the United States. The principal properties of the company are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.